Sanofi and pan-Canadian alliance sign Sarclisa letter of intent
Sanofi and the pan-Canadian Pharmaceutical Alliance signed a letter of intent for Sarclisa (isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patients.